Updated information about biosimilars, biologics, approvals, interchangeability, immunogenicity, europe, fda. All news about biosimilars on biosimilarnews.com
http://www.biosimilarnews.com/
TODAY'S RATING
#679,974
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
0.6 seconds
WHOIS PRIVACY PROTECTION SERVICE, INC.
WHOIS AGENT
PO ●●●639
C/O BIO●●●●●●●EWS.COM
KIR●●●AND , WA, 98083
US
View this contact
WHOIS PRIVACY PROTECTION SERVICE, INC.
WHOIS AGENT
PO ●●●639
C/O BIO●●●●●●●EWS.COM
KIR●●●AND , WA, 98083
US
View this contact
WHOIS PRIVACY PROTECTION SERVICE, INC.
WHOIS AGENT
PO ●●●639
C/O BIO●●●●●●●EWS.COM
KIR●●●AND , WA, 98083
US
View this contact
BUY YOUR DOMAIN
12
YEARS
10
MONTHS
6
DAYS
ENOM, INC.
WHOIS : whois.enom.com
REFERRED : http://www.enom.com
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
30
SITE IP
173.254.28.54
LOAD TIME
0.575 sec
SCORE
6.2
Biosimilar News — Biosimilars, Biosimilar, News, Biosimilar News, Biobetter, Biologicals, Monoclonal Antibodies, Generic Biologics, Generics, Biologics, Biopharmaceuticals, Biogenerics, Biologicals | biosimilarnews.com Reviews
https://biosimilarnews.com
Updated information about biosimilars, biologics, approvals, interchangeability, immunogenicity, europe, fda. All news about biosimilars on biosimilarnews.com
biosimilarnews.com
Pfizer starts biosimilar rituximab Phase I/II trial
http://www.biosimilarnews.com/pfizer-starts-biosimilar-rituximab-phase-iii-trial
In order not to miss any updates, follow us on Twitter. Or sign up for our Newsletter. Contact us via E-Mail. Follow us on Twitter. Follow us on LinkedIn. Sign up for our newsletter. A biobetter trastuzumab is on the way. EGA president calls on Member States to boost market access for biosimilars in the EU. 3rd Forum on Biosimilars. Pfizer starts biosimilar rituximab Phase I/II trial. World’s first biosimilar antibody* is approved in Korea. A biosimilar manufacturer: Celltrion. You are here: Home. The pr...
Site Map
http://www.biosimilarnews.com/site-map
In order not to miss any updates, follow us on Twitter. Or sign up for our Newsletter. Contact us via E-Mail. Follow us on Twitter. Follow us on LinkedIn. Sign up for our newsletter. A biobetter trastuzumab is on the way. EGA president calls on Member States to boost market access for biosimilars in the EU. 3rd Forum on Biosimilars. Pfizer starts biosimilar rituximab Phase I/II trial. World’s first biosimilar antibody* is approved in Korea. A biosimilar manufacturer: Celltrion. Oncobiologics announced fi...
Guidelines — Biosimilar News
http://www.biosimilarnews.com/category/guidelines
In order not to miss any updates, follow us on Twitter. Or sign up for our Newsletter. Archive for Category: "Guidelines". FDA releases draft biosimilar labeling guidance. The US. FDA has released draft guidelines on labeling of biosimilars but problems remain in world’s biggest biopharma market. Read full story →. Contact us via E-Mail. Follow us on Twitter. Follow us on LinkedIn. Sign up for our newsletter. A biobetter trastuzumab is on the way. 3rd Forum on Biosimilars. March 29, 2016 9:50 AM. On Deli...
News/Headlines — Biosimilar News
http://www.biosimilarnews.com/category/news
In order not to miss any updates, follow us on Twitter. Or sign up for our Newsletter. Archive for Category: "News/Headlines". Coherus BioSciences announces positive Phase III results for CHS-1420 (Humira biosimilar candidate) in psoriasis patients. Coherus BioSciences, Inc., reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira) biosimilar candidate. Read full story →. Contact us via E-Mail. Follow us on Twitter. Follow us on LinkedIn. 3rd Forum on Biosimilars.
Policies — Biosimilar News
http://www.biosimilarnews.com/category/policies
In order not to miss any updates, follow us on Twitter. Or sign up for our Newsletter. Archive for Category: "Policies". 70 stakeholder groups call on the FDA, urging distinguishable, meaningful suffixes for biosimilars. In a letter to the FDA this week, a 70-group coalition of healthcare stakeholders including patient and provider organizations and others urged the use of distinguishable, meaningful suffixes for biosimilars. Read full story →. Contact us via E-Mail. Follow us on Twitter. GMiA becomes Ge...
TOTAL PAGES IN THIS WEBSITE
20
14th Annual Biosimilar Medicines Group Conference
http://www.egaevents.org/bios
14th Annual Biosimilar Medicines Group Conference. THE GATHERING OF THE WORLD'S BIOSIMILARS EXPERTS. Grange Tower Bridge Hotel. 2016 CONFERENCE SESSION OUTLINE. FULL PROGRAMME ( htm version. HOTEL RESERVATION To check the availability as well as the best rate available please contact Antonia Teixeira at The Grange Tower Bridge Hotel (45 Prescot Street London E1 8GP, UK) P: 44 (0) 207 959 5000 - 44 (0) 207 959 5105 E: towerbridge.groups@grangehotels.com. SEE THE 2015 SLIDESHOW. Leah Christl, PhD. Medical ...
mediapartner | Biosimilars Clinical Studies and Analytical Similarity Summit
https://biosimilarssummit.iqpc.com/mediapartner
Main Conference Day One. Main Conference Day Two. 21-22 February, 2017. The Clinical Research Association of Canada (CRAC). Http:/ www.craconline.ca. Http:/ www.gabionline.net. Http:/ www.biopractice.com/. BioPractice as a platform focuses to be the core part of learning and development for the life science industry as well as the academia. It has been built to meet the objective of the learning and development in the areas of latest trends and practices of the industry, regulation updates in the ind...
amp biosimilars | Pure-Play Biosimilar Pharmaceuticals
http://www.ampbiosimilars.com/de/startseite.html
Amp biosimilars Pure-Play Biosimilar Pharmaceuticals. Markt und Anwendungsgebiete für Biosimilars. Gute Aussichten für Biosimilars. Amp biosimilars: Biotechnologie 2.0. Ist eines der führenden europäischen Biosimilar-Unternehmen. Amp biosimilars AG ist durch ihren einzigartigen Ansatz in der Lage, Biosimilars günstiger und effizienter zu entwickeln als vergleichbare Wettbewerber. Das Management und seine Partner repräsentieren mehr als 125 Jahre Erfahrung und Expertise im Bereich Biosimilars. Amp biosimi...
amp biosimilars | Pure-Play Biosimilar Pharmaceuticals
http://www.ampbiosimilars.com/en/home.html
Development of Biosimilar Medicines. Biosimilars Market and Therapeutic Areas. The Perspective: Many More Biosimilars to Come. Amp biosimilars: Biotechnology 2.0. Is one of Europe’s leading pure play biosimilar companies. Amp biosimilars AG has created a unique platform which enables it to develop biosimilars faster, cheaper and more efficiently than anyone else before. Its management and partners represent more than 125 years of combined excellence and expertise in biosimilars. Why amp biosimilars AG?
forumbiossimilares.blogspot.com
Fórum Biossimilares: Celltrion e o Remsima
http://forumbiossimilares.blogspot.com/2012/08/celltrion-e-o-remsima.html
FÓRUM DE DEBATES BIOSSIMILARES. FÓRUM NACIONAL DE BIOSSIMILARES 2010. LEGISLAÇÃO - MEDICAMENTOS BIOLÓGICOS E BIOSSIMILARES. O II Fórum Latino Americano de Biossimilares e III Fórum Brasileiro de Biossimilares. São constituidos por um ciclo de palestras direcionado à comunidade médico-científica, a gestores do sistema público de saúde e a demais interessados, a fim de promover o debate acerca das novas diretrizes da área dos medicamentos biológicos. Segunda-feira, 20 de agosto de 2012. Um dos seus últimos...
TOTAL LINKS TO THIS WEBSITE
30
biosimilarmedication.com
Welcome to biosimilarmedication.com. This domain is parked free of charge with NameSilo.com. NameSilo offers the cheapest domains on the Internet as well as:. FREE Parking (you keep 100% of the revenue! Industry Leading Domain Security. Powerful Domain Management Tools. Fast, Simple and Easy Processes. Biosimilarmedication.com Privacy Policy.
biosimilarmedication.info
Welcome to biosimilarmedication.info. This domain is parked free of charge with NameSilo.com. NameSilo offers the cheapest domains on the Internet as well as:. FREE Parking (you keep 100% of the revenue! Industry Leading Domain Security. Powerful Domain Management Tools. Fast, Simple and Easy Processes. Biosimilarmedication.info Privacy Policy.
biosimilarmedicine.com - This website is for sale! - biotechnology pharmaceutical drug biosimilar Resources and Information.
The domain biosimilarmedicine.com. May be for sale by its owner! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
biosimilarmedicines.com - This website is for sale! - biotechnology pharmaceutical drug biosimilar Resources and Information.
The domain biosimilarmedicines.com. May be for sale by its owner! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
biosimilarmeds.com - This website is for sale! - biotechnology pharmaceutical drug biosimilar Resources and Information.
The domain biosimilarmeds.com. May be for sale by its owner! This page provided to the domain owner free. By Sedo's Domain Parking. Disclaimer: Domain owner and Sedo maintain no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo or domain owner and does not constitute or imply its association, endorsement or recommendation.
Biosimilar News — Biosimilars, Biosimilar, News, Biosimilar News, Biobetter, Biologicals, Monoclonal Antibodies, Generic Biologics, Generics, Biologics, Biopharmaceuticals, Biogenerics, Biologicals
In order not to miss any updates, follow us on Twitter. Or sign up for our Newsletter. MSD launches Europe’s first biosimilar Herceptin in UK. The first biosimilar version of Roche’s blockbuster breast cancer drug Herceptin has been launched in the UK by MSD under the Ontruzant brand name. Read full story →. Contact us via E-Mail. Follow us on Twitter. Follow us on LinkedIn. Sign up for our newsletter. Popular Posts of last 30 days. MSD launches Europe’s first biosimilar Herceptin in UK. March 12, 2018 0.
Biosimilar Pharmacy
Welcome to biosimilarpharmacy.com. Is an important exact-match domain name for a mass market prescription drug retailer or pharmacy benefits management (PBM) organization. As access to biosimilars. And other follow-on biologics. Expands, this domain name will be of increasing value to a pharmacy or PBM organization ready to support this vital area of medicine. Further information on domains in this area can be found at FollowOnBiologic.com. THIS DOMAIN NAME IS FOR SALE. Top Chops on the Net.
biosimilarregulations.com - This website is for sale! - biosimilars Resources and Information.
The owner of biosimilarregulations.com. Is offering it for sale for an asking price of 950 USD! The owner of biosimilarregulations.com. Is offering it for sale for an asking price of 950 USD! This page provided to the domain owner free. By Sedo's Domain Parking.
biosimilars-biologics.pharmaceuticalconferences.com
Biosimilars Global Events | USA | Europe | Asia | Middle East | 2015 | 2016
Conferences, Meetings, Exhibitions, Symposiums and Workshops. Regulatory Affairs 2015,USA. Ethnopharmacology 2016, USA. Pharmacology 2016, UK. Pain Medicine 2016, USA. Industrial Pharmacy 2106, UAE. Asian Pharma 2016, Malaysia. Symposium and Contact Details. October 26, 2015. October 27, 2015. October 28, 2015. Brochure and Contact Details. Speaker Guidelines and FAQ. 4th International Conference and Exhibition on. October 26-28, 2015 Baltimore, USA. Click here for Biosimilars 2016. 2nd Annual Congress on.
Oxford Global Marketing – 5th Biennial Biosimilars & Biobetters Congress, 16 – 17 April 2018, Novotel London West, London, UK
5th Biennial Biosimilars and Biobetters Congress 2018. 16 - 17 April 2018, London, UK. Free Webinar Recording 2018. 11th Annual Proteins & Antibodies Congress. 5th Annual Peptides Congress. An Example of Delegate Attendance. Free Webinar Recording 2018. Sponsorship at a Glance. 2018 Network & Programme Sponsors. View Sponsor White Papers. Free Webinar Recording 2018. 5th Biennial Biosimilars & Biobetters Congress 2018. Two-day interactive conference addressing the following topics:. Application for compl...
SOCIAL ENGAGEMENT